This study will evaluate the safety and efficacy of EPI-743 in participants with severe mitochondrial respiratory chain diseases who are considered to be within 90 days of end-of-life care.
Study Type
EXPANDED_ACCESS
EPI-743 (oral solution \[100 mg/mL\] or liquid-filled capsules \[100 mg or 200 mg\]) will be administered per dose and schedule specified in the arm.
UCLA
Los Angeles, California, United States
CHOC Children's Clinic
Orange, California, United States
Lucille Packard Children's Hospital
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Palo Alto, California, United States
UCSD
San Diego, California, United States
Stanford Children's Health
Stanford, California, United States
Emory University
Decatur, Georgia, United States
CUMC (Columbia University)
New York, New York, United States
Carolinas Medical Center
Charlotte, North Carolina, United States
Akron Children's Hospital
Akron, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
...and 6 more locations